What is DuraGraft®?
DuraGraft is the first and only approved solution for the preservation of vascular conduits to reduce complications of vein graft disease and vein graft failure. An estimated 49% of patients going through CABG procedures experience at least one vein graft failure in the first year following surgery while an individual vein graft has a 30% chance of failure within the first year.
This single-use intraoperative vascular graft treatment improves clinical outcomes by preventing ischemic injury and subsequent reperfusion injury thereby maintaining endothelial function, thereby reducing the incidence and complications of graft failure.
DuraGraft is not yet available for sale in the United States.
Product Description
DuraGraft Vascular Conduit Solution is intended for use during the harvesting and grafting interval of vascular surgery to maintain structural and functional integrity of vascular conduits.
How does DuraGraft® compare to the Current Standard of Care?
DuraGraft is Emerging as the New Standard of Care for Coronary Artery Bypass Surgery Globally
|
Limitations of the current standard of care solutions Saline, blood and buffered solutions are widely used but are not indicated for use and do not protect against Ischemic Injury and do not protect against subsequent vein graft disease and graft failure |
Clinical Needs
 |
49% patient level graft failure |
 |
Economic Burden on Healthcare System |
 |
Vein Graft Failure is associated with poor clinical outcomes post-CABG |
DuraGraft® Market Size
$16.1B
Was the global coronary artery bypass graft procedures market size in 2018 & It is anticipated to expand at a CAGR of 1.7% from 2019 to 2025.*
Up to ~1,000,000
Number of Heart bypass (CABG) procedures estimated to be performed worldwide every year.
Up to 350,000
CABG surgeries performed annually in the US
